MediWound (MDWD)
(Delayed Data from NSDQ)
$20.10 USD
+1.13 (5.96%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $20.04 -0.06 (-0.30%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$20.10 USD
+1.13 (5.96%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $20.04 -0.06 (-0.30%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Zacks News
MediWound (MDWD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MediWound (MDWD) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
MediWound (MDWD) delivered earnings and revenue surprises of -30% and 24.93%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
CASI Pharmaceuticals, Inc. (CASI) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
CASI Pharmaceuticals, Inc. (CASI) delivered earnings and revenue surprises of 25.49% and 1.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
VYNE Therapeutics Inc. (VYNE) delivered earnings and revenue surprises of 0% and 67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
MediWound (MDWD) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
MediWound (MDWD) delivered earnings and revenue surprises of -30% and 11.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
FibroGen (FGEN) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
FibroGen (FGEN) delivered earnings and revenue surprises of 17.02% and 18.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
MediWound (MDWD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MediWound (MDWD) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
MediWound (MDWD) delivered earnings and revenue surprises of -9.09% and 1.31%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Ayala Pharmaceuticals, Inc. (AYLA) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Ayala Pharmaceuticals, Inc. (AYLA) delivered earnings and revenue surprises of 7.04% and 57.99%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
4D Molecular Therapeutics, Inc. (FDMT) delivered earnings and revenue surprises of -12.33% and 39.05%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
MediWound (MDWD) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
MediWound (MDWD) delivered earnings and revenue surprises of 6.25% and 2.89%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Catalyst Pharmaceutical (CPRX) Q4 Earnings Lag Estimates
by Zacks Equity Research
Catalyst (CPRX) delivered earnings and revenue surprises of -25% and 0.37%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Altimmune, Inc. (ALT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 23.44% and 2,145.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Dipexium Pharmaceuticals, Inc. (PLXP) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Dipexium Pharmaceuticals, Inc. (PLXP) delivered earnings and revenue surprises of -5.80% and 17.51%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
MediWound (MDWD) Could Find Support Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
MediWound (MDWD) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Earnings Preview: MediWound (MDWD) Q4 Earnings Expected to Decline
by Zacks Equity Research
MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MediWound (MDWD) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
MediWound (MDWD) delivered earnings and revenue surprises of 0.00% and 13.79%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate MediWound (MDWD) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MediWound (MDWD) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
MediWound (MDWD) delivered earnings and revenue surprises of -9.09% and 6.36%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will MediWound (MDWD) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bear of the Day: Vericel (VCEL)
by Kevin Cook
Restoring cartilage in sports medicine and rebuilding skin after severe burns gave this small-cap big upside
MediWound (MDWD) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
MediWound (MDWD) delivered earnings and revenue surprises of 16.67% and 10.32%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate MediWound (MDWD) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MediWound (MDWD) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
MediWound (MDWD) delivered earnings and revenue surprises of 45.45% and 19.48%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
MediWound (MDWD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.